Physician profile
Wendy Masterman
NPI 1891006888
$1,792.36
in general payments reported to CMS, 2019-2025
21 companies · $627 in 2025
The $627 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $108 · 2021: $134 · 2022: $148 · 2023: $283 · 2024: $493 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $280.05 | 2022-2025 | Azstarys |
| Pfizer INC. | $237.84 | 2020-2024 | |
| Supernus Pharmaceuticals, INC. | $205.99 | 2024-2025 | Qelbree |
| Cranial Technologies, INC | $195.59 | 2020-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $181.19 | 2025 | Jornay Pm |
| Alk-Abello, INC | $121.28 | 2025 | Neffy, Odactra, Grastek |
| Takeda Pharmaceuticals U.S.A., INC. | $109.87 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $90.42 | 2020-2024 | Jornay Pm |
| Tris Pharma INC | $65.90 | 2023-2025 | Dyanavel Xr |
| Sobi, INC | $59.26 | 2022-2023 | |
| Vertical Pharmaceuticals, LLC | $48.39 | 2024-2025 | Relexxii |
| Astrazeneca Pharmaceuticals LP | $48.16 | 2023-2024 | Flumist Quadrivalent |
| Noven Therapeutics, LLC | $44.78 | 2024-2025 | Xelstrym |
| Glaxosmithkline, LLC. | $26.04 | 2022-2023 | Pediarix, Bexsero |
| Phadia US INC. | $22.49 | 2024 | Immunocap |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.49 | 2024 | Vaxelis, Gardasil, Gardasil 9 |
| Pbg Puerto Rico LLC | $19.25 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.37 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Masterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.